The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy (as measured by the rate of
recurrent symptomatic Venous Thromboembolism [VTE] (i.e., Pulmonary thromboembolism [PE] and
Deep Vein Thrombosis [DVT])) and safety of GSK576428 as the initial treatment in subjects
with acute symptomatic DVT in an open-label design.